EP Patent

EP2231159A1 — Method of treating arthritis

Assigned to AbbVie Inc · Expires 2010-09-29 · 16y expired

What this patent protects

Methods of preventing or treating arthritis is disclosed.

USPTO Abstract

Methods of preventing or treating arthritis is disclosed.

Drugs covered by this patent

lenvatinib-mesylate (LENVATINIB MESYLATE)

Patent Metadata

Patent number: EP2231159A1
Jurisdiction: EP
Classification: —
Expires: 2010-09-29
Drug substance claim: No
Drug product claim: No
Assignee: AbbVie Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.